985 resultados para California. State Board of Equalization


Relevância:

100.00% 100.00%

Publicador:

Resumo:

The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug law.

Relevância:

100.00% 100.00%

Publicador:

Resumo:

The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug law.

Relevância:

100.00% 100.00%

Publicador:

Resumo:

The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug law.

Relevância:

100.00% 100.00%

Publicador:

Resumo:

The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug law.

Relevância:

100.00% 100.00%

Publicador:

Resumo:

The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug law.

Relevância:

100.00% 100.00%

Publicador:

Resumo:

The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug law.

Relevância:

100.00% 100.00%

Publicador:

Resumo:

The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug law.

Relevância:

100.00% 100.00%

Publicador:

Resumo:

The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug law.

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Audit report of Debt Service and Coverage for Iowa State University of Science and Technology as of June 30, 2014

Relevância:

100.00% 100.00%

Publicador:

Resumo:

The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug law.

Relevância:

100.00% 100.00%

Publicador:

Resumo:

The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug law.

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Annual Report from the Iowa Board of Parole

Relevância:

100.00% 100.00%

Publicador:

Resumo:

AB Summary: Steady state concentrations of (S)- and (R)-mianserin and desmethylmianserin were measured in 21 homozygous extensive metabolizers (as determined by genotyping for mutations 3 [or A] and 4 [or B]), in seven heterozygous extensive metabolizers and in one poor metabolizer of debrisoquine, as well as in one patient receiving very high doses of mianserin (360 mg/day) and fluoxetine (160 mg/day), a strong cytochrome P450IID6 inhibitor. The mean dose of mianserin was (mean +/- SD, range: 67 +/- 63, 10 to 360 mg/day). High dispersions of the (S)/(R)-mianserin and desmethylmianserin ratios were observed (mean +/- SD, range: 2.10+/- 1.01, 0.64 to 4.76, and 0.29 +/- 0.14, 0.08 to 0.57, respectively). The highest (S)/(R)-mianserin ratio was calculated for the poor metabolizer (4.76) agreeing with those results of a single-dose study with poor and extensive metabolizers of debrisoquine, in that the cytochrome P450IID6 is probably involved in the metabolism of mianserin with an enantioselectivity for the (S)-enantiomer. Nevertheless, the mean concentration-to-dose ratios for (S)- or (R)-mianserin or desmethylmianserin were not significantly different between homozygous and heterozygous extensive metabolizers, and no particular values were measured in the poor metabolizer nor in the patient receiving fluoxetine. Furthermore, the(S)/(R)-mianserin ratio measured in the PM was only slightly higher than the second highest ratio (3.85) of an homozygous extensive metabolizer, whereas no particular value (2.92) was calculated for the patient taking fluoxetine. Finally, no significant differences in (S)/(R)-mianserin or(S)/(R)-desmethylmianserin were calculated between homozygous and heterozygous extensive metabolizers. Although the number of patients included in this study is too low to allow definite conclusions, the results suggest that the debrisoquine genotype has only a moderate influence on the steady state concentrations of the enantiomers of mianserin and desmethylmianserin. (C) Lippincott-Raven Publishers

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Report on the State University of Iowa, Iowa City, Iowa for the year ended June 30, 2014

Relevância:

100.00% 100.00%

Publicador:

Resumo:

The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug law.